JP2015506705A5 - - Google Patents

Download PDF

Info

Publication number
JP2015506705A5
JP2015506705A5 JP2014555853A JP2014555853A JP2015506705A5 JP 2015506705 A5 JP2015506705 A5 JP 2015506705A5 JP 2014555853 A JP2014555853 A JP 2014555853A JP 2014555853 A JP2014555853 A JP 2014555853A JP 2015506705 A5 JP2015506705 A5 JP 2015506705A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
residues
acid sequence
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014555853A
Other languages
English (en)
Japanese (ja)
Other versions
JP6336915B2 (ja
JP2015506705A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/024957 external-priority patent/WO2013119683A1/en
Publication of JP2015506705A publication Critical patent/JP2015506705A/ja
Publication of JP2015506705A5 publication Critical patent/JP2015506705A5/ja
Application granted granted Critical
Publication of JP6336915B2 publication Critical patent/JP6336915B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014555853A 2012-02-07 2013-02-06 計算で最適化した広い反応性を示すh3n2、h2n2、およびb型インフルエンザウイルスの抗原 Expired - Fee Related JP6336915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261596014P 2012-02-07 2012-02-07
US61/596,014 2012-02-07
PCT/US2013/024957 WO2013119683A1 (en) 2012-02-07 2013-02-06 Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses

Publications (3)

Publication Number Publication Date
JP2015506705A JP2015506705A (ja) 2015-03-05
JP2015506705A5 true JP2015506705A5 (cg-RX-API-DMAC7.html) 2016-03-03
JP6336915B2 JP6336915B2 (ja) 2018-06-06

Family

ID=48947966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555853A Expired - Fee Related JP6336915B2 (ja) 2012-02-07 2013-02-06 計算で最適化した広い反応性を示すh3n2、h2n2、およびb型インフルエンザウイルスの抗原

Country Status (14)

Country Link
US (1) US9234008B2 (cg-RX-API-DMAC7.html)
EP (1) EP2812348A4 (cg-RX-API-DMAC7.html)
JP (1) JP6336915B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140127827A (cg-RX-API-DMAC7.html)
CN (1) CN104136456A (cg-RX-API-DMAC7.html)
AU (2) AU2013217166B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014018884A2 (cg-RX-API-DMAC7.html)
CA (1) CA2863981A1 (cg-RX-API-DMAC7.html)
HK (1) HK1203524A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN05805A (cg-RX-API-DMAC7.html)
MX (1) MX2014009148A (cg-RX-API-DMAC7.html)
RU (2) RU2653756C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201404653UA (cg-RX-API-DMAC7.html)
WO (1) WO2013119683A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3431100B1 (en) * 2010-09-14 2021-09-08 University of Pittsburgh- Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
CN103732749B (zh) 2011-06-20 2017-03-29 高等教育联邦系统-匹兹堡大学 计算优化的宽反应性的h1n1流感抗原
JP6175452B2 (ja) 2012-02-13 2017-08-02 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション ヒトおよびトリh5n1インフルエンザのための、計算で最適化した反応性の広い抗原
MY166953A (en) 2012-03-30 2018-07-25 Univ Pittsburgh Commonwealth Sys Higher Education Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses
AU2013352179B2 (en) 2012-11-27 2017-12-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
CN107847579A (zh) * 2014-12-19 2018-03-27 俄勒冈健康与科学大学 人和禽h5n1流感的计算优化的广泛反应性抗原的协同共同给药
AU2016270979B2 (en) 2015-06-02 2020-11-12 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
CA2986701A1 (en) 2015-06-09 2016-12-15 Sanofi Pasteur, Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
US10485864B2 (en) 2015-09-21 2019-11-26 Oregon Health & Science University Characterization of influenza vaccines
AU2017272344B2 (en) 2016-06-02 2022-03-03 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
CN109563138B (zh) 2016-06-03 2022-09-23 圣诺菲·帕斯图尔公司 经改造的流感血凝素多肽的修饰
WO2020014675A1 (en) * 2018-07-13 2020-01-16 University Of Georgia Research Foundation Methods for generating pan-epitopic immunogens of influenza h3 virus, compositions and methods of use thereof
EP3856239A2 (en) * 2018-09-28 2021-08-04 The Chancellor, Masters and Scholars of the University of Cambridge Vaccines and methods
WO2024167855A1 (en) * 2023-02-06 2024-08-15 Emergent Product Development Gaithersburg Inc. Influenza hemagglutinin constructs and compositions

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP2388015A1 (en) 2000-03-02 2011-11-23 Emory University DNA expression vectors and methods of use
US20050181459A1 (en) 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
CA2529647C (en) 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2006104615A2 (en) 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
WO2007072214A2 (en) 2005-12-19 2007-06-28 Novartis Vaccines And Diagnostics Srl Methods of clustering gene and protein sequences
US20080045472A1 (en) 2006-03-31 2008-02-21 Council Of Scientific And Industrial Research Bharat Biotech Targets for human micro rnas in avian influenza virus (h5n1) genome
WO2007130327A2 (en) 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
EP2522678A1 (en) * 2006-05-15 2012-11-14 Sea Lane Biotechnologies, LLC Neutralizing antibodies to influenza viruses
US8980281B2 (en) 2006-09-05 2015-03-17 Academia Sinica High-yield transgenic mammalian expression system for generating virus-like particles
HRP20130163T1 (hr) 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
WO2008040060A1 (en) 2006-10-04 2008-04-10 The University Of Queensland Vlp based vaccine delivery system
EP2160198A2 (en) * 2007-05-31 2010-03-10 Statens Serum Institut Influenza vaccines
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
WO2009073330A2 (en) 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
KR101956910B1 (ko) * 2008-01-21 2019-03-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(VLPs)
US7981428B2 (en) 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
US20120034253A1 (en) 2008-09-25 2012-02-09 Fraunhofer Usa, Inc. Influenza Vaccines, Antigens, Compositions, and Methods
US20110177122A1 (en) 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
CN103585643A (zh) 2009-04-03 2014-02-19 梅里亚有限公司 运载新城疫病毒的禽疫苗
WO2011087839A1 (en) * 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
US8298820B2 (en) * 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
EP3431100B1 (en) 2010-09-14 2021-09-08 University of Pittsburgh- Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
CN103732749B (zh) 2011-06-20 2017-03-29 高等教育联邦系统-匹兹堡大学 计算优化的宽反应性的h1n1流感抗原

Similar Documents

Publication Publication Date Title
JP2015506705A5 (cg-RX-API-DMAC7.html)
JP6957580B2 (ja) 新規多価ナノ粒子に基づくワクチン
RU2014101401A (ru) Антигены вируса гриппа h1n1 с широким спектром активности, оптимизированные с применением вычислительных средств
RU2018113521A (ru) Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b
RU2017141447A (ru) Рекомбинантные полипептиды гемагглютинина (ha) вируса гриппа, композиции, содержащие их, и способы вызова иммунного ответа в отношении вируса гриппа h1n1
JP2016505538A5 (cg-RX-API-DMAC7.html)
WO2020234300A1 (en) A subunit vaccine for treatment or prevention of a respiratory tract infection
JP2014530010A5 (cg-RX-API-DMAC7.html)
JP2009544318A5 (cg-RX-API-DMAC7.html)
RU2019139064A (ru) Композиции и способы для лечения цитомегаловируса
JP2012095652A5 (cg-RX-API-DMAC7.html)
JP2015501840A5 (cg-RX-API-DMAC7.html)
JP2014502156A5 (cg-RX-API-DMAC7.html)
JP2012511579A5 (cg-RX-API-DMAC7.html)
JP2010535026A5 (cg-RX-API-DMAC7.html)
JP2015509707A5 (cg-RX-API-DMAC7.html)
JP2015505299A5 (cg-RX-API-DMAC7.html)
JP2014507146A5 (cg-RX-API-DMAC7.html)
JP2015524422A5 (cg-RX-API-DMAC7.html)
JP2014519817A5 (cg-RX-API-DMAC7.html)
RU2015124805A (ru) Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вируса гриппа h1n1
JP2015521206A5 (cg-RX-API-DMAC7.html)
JP2019500320A5 (cg-RX-API-DMAC7.html)
JP5560510B2 (ja) カプシドタンパク質及びその利用
Liu et al. A self-assembling nanoparticle: Implications for the development of thermostable vaccine candidates